Press Release

Quinten Health, Deeplink Medical, and *Institut de Cancérologie de l'Ouest* (ICO) partner to improve the adverse events monitoring and management in early phase clinical trials, using a digital device enhanced by artificial intelligence.

Paris, November 15th, 2021 – The partnership will allow INCa (Institut National du Cancer) accredited hospitals of early phase (CLIP) and to industrial sponsors to improve the collection, identification, and characterization of adverse events, as well as the evaluation of their imputability to the treatment, thus improving the development of cancer drugs and patient care.

A STRATEGIC PARTNERSHIP TO DEVELOP A DIGITAL PLATFORM ENRICHED BY ARTIFICIAL INTELLIGENCE

The Institut de Cancérologie de l'Ouest, an expert center in oncology based in Angers and Nantes, Deeplink Medical, a Lyon-based company digitizing medical imaging and offering solutions for patient pathway optimization, and Quinten Health, a Paris-based company specialized in the analysis of real-world data and in design and development of decision support solutions based on artificial intelligence, have announced a strategic partnership to augment the collection and evaluation of data in early phase clinical trials in oncology.

The main objective of this partnership is to develop a digital platform enhanced by artificial intelligence and aimed at standardizing the collection of adverse events data.

EARLY PHASE TRIALS: INNOVATING TO OPTIMIZE DATA COLLECTION

Today, between 500 and 600 trials are managed by the ICO's teams in Nantes and Anjou, including about forty early phase trials. The collection of adverse events data is an essential step of clinical trials. This data collected throughout the trials constitute an essential source of information.

In early phase trials, the documentation of adverse events occurring between treatment courses represents a significant amount of work, which can be optimized, consolidated, and standardized.

Indeed, a patient during the consultation might forget certain side effects, their nature, their intensity, and their date of onset. The data entry can also sometimes be incomplete or lacking in precision. Similarly, the evaluation of the imputability of these adverse events can be improved and and objectified.

This issue, which is addressed by the ICO's physicians and CRAs (Clinical Research Associates) gave birth to the **"INTERCURE" project,** which aims at answering the following questions:

- How to improve **the quality and evaluation of the collected data**?
- How to save **time in the collection of information** for the physician and the clinical research team?
- How to **maintain a link with the patient** between treatments during an early phase trial?

"*Collecting side effects data, in real time and by the patient, is essential for the development of new drugs via therapeutic trials. This is the INTERCURE project!"* explains Dr. Victor SIMMET, Medical Oncologist at ICO in Angers.

"*To be able to meet the requirements of Good Clinical Practices while saving time, increasing completeness and improving the traceability, this is essential for us*", says Gwenaëlle LEWRICH, clinical research investigator at ICO in Nantes.

TWO EXPERTISES COMPLETING THAT OF ICO

Deeplink Medical, a **specialist in innovative digital solutions for the medical sector**, brings to the project its technologies and know-how to:

- Standardize the collection of adverse events data, and facilitate the communication around the data
- Save time for all those involved in the collection process, and each of its stages
- Guarantee perfect traceability
- Consolidate structured and easily exploitable data

The contribution of Quinten Health, a **specialist in artificial intelligence-powered data analysis and decision support in the health sector**, will focus on the objectification of adverse events immutability to treatments.

"*We are delighted to be able to work with the ICO and Quinten Health teams to meet the need for patient self-reporting and the reporting of adverse events by healthcare professionals. We will make it possible to collect the adverse events data in a secure, systematic and structured way, to improve their care even further improve their care by the center's medical team, while facilitating research,"* says Hugues LAJOIE, CEO and co-founder of Deeplink Medical.

"*The quality of the information collected on the patient experience is crucial, especially in the context of early stage oncology trials. It conditions the ability of healthcare professionals to adapt their therapeutic decisions and the ability of pharmaceutical companies to detect potential signals. The combination of ICO's clinical expertise, Deeplink Medical's proven digital technologies know how, and real-life data science combined with our artificial intelligence technologies, allows us to collectively provide an original and effective response to this need,"* comments **Alexandre TEMPLIER, President and co-founder of Quinten Health**

The project started on October 21, 2021 with the kick-off meeting of the entire Project Team. Alongside Quinten Health and Deeplink Medical, the team include the Nantes-Angers ICO physicians: Marie ROBERT, Victor SIMMET, Fréderic BIGOT, Gwenaëlle LEWANDOWSKI, as well as the members of the Clinical Research Department and of the Information Systems Department.

About Institut de Cancérologie de l'Ouest (ICO), an expert center

The ICO, a Cancer Research Center, welcomes nearly 45,000 patients each year (45,497 in 2020) in its two institutions in the Pays de la Loire region:

- o In Angers (head office)
- o In Nantes/Saint-Herblain

Advanced medicine at the service of patients: specialized in oncology, ICO professionals accompany patients at every stage of their care, in a personalized, innovative and multidisciplinary way. From rapid diagnosis to surgery, chemotherapy and radiotherapy, the care provided also extends to supportive care, which is highly developed in the institution.

Integration of care, research and innovation: the ICO's research activity, a mission in its own right, ranges from the fundamental level to clinical trials, including translational research. It covers all cancer disciplines: medical oncology, radiotherapy, surgery, anesthesia, nuclear medicine, medical imaging, support care, and human sciences.

"*Accompanying Innovation in Oncology*" is the motto of the Innovation Division, which is now integrated into the new Development and Innovation Department, created in May 2021, whose mission is to support internal and external project leaders, from the idea to the operational deployment of the innovation.

Through its teaching mission, the Institute trains tomorrow's professionals in oncology.
https://www.institut-cancerologie-ouest.com/

About Deeplink Medical

Based in Lyon and founded in 2014, Deeplink Medical digitalizes medical imaging by offering platforms to optimize and accelerate the patient care.
At the initiative of 5 radiologists, Deeplink Medical builds its solutions around the patient, based on the latest technological and medical innovations, and according to the best practices (ISO 27001 and HDS certifications, CE marking for medical devices).
Today, Deeplink Medical has about fifty employees working in three areas of excellence: medical, R&D and operational. They work on the continuous development of Deeplink Medical's platforms. More than a hundred health institutions in France trust us and have chosen ITIS for radiological and teleradiological examinations, MIRIO for oncological monitoring and evaluation of therapeutic response, and DICOM image transfer solution: the DLMbox.
https://www.deeplink-medical.com/

About Quinten Health

Quinten Health, headquartered in Paris, France, is a spin-off from Quinten, the French pioneer in artificial intelligence and interpretable data science applied to healthcare since 2008. Quinten Health is a team of 50+ healthcare data scientists, modelers and biomedical and public health experts specialized in real-world data and have delivered over 400 projects. Quinten Health provides healthcare stakeholders (industry, hospitals, and regulatory agencies) with AI/ML solutions for precision care.
https://www.quinten-health.com/